Oral antihyperglycemic therapy for type 2 diabetes mellitus
Open Access
- 18 January 2005
- journal article
- review article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 172 (2) , 213-226
- https://doi.org/10.1503/cmaj.1031414
Abstract
DIABETES MELLITUS IS A CHRONIC DISEASE that is growing in prevalence worldwide. Pharmacologic therapy is often necessary to achieve optimal glycemic control in the management of diabetes. Orally administered antihyperglycemic agents (OHAs) can be used either alone or in combination with other OHAs or insulin. The number of available OHAs has increased significantly in the last decade, which translates into more therapeutic options and complex decision-making for physicians. This review article is designed to help with these decisions. We review the mechanism of action, efficacy and side effects of the different classes of OHAs (α-glucosidase inhibitors, biguanides, insulin secretagogues, insulin sensitizers and intestinal lipase inhibitor) and discuss the current recommendations for their use.This publication has 87 references indexed in Scilit:
- Clinical Pharmacokinetics of NateglinideClinical Pharmacokinetics, 2004
- Clinical Pharmacokinetics and Pharmacodynamics of RepaglinideClinical Pharmacokinetics, 2002
- Insulin signalling and the regulation of glucose and lipid metabolismNature, 2001
- Global and societal implications of the diabetes epidemicNature, 2001
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 1998
- Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative StudyHormone and Metabolic Research, 1996
- A Comparison of Acarbose Versus Metformin as an Adjuvant Therapy in Sulfonylurea-Treated NIDDM PatientsDiabetes Care, 1996